Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338242 | 0.96 | BMP1 (0.35) | RENGRM5BMP1 | |
| SCHEMBL3268517 | 0.95 | REN (0.34) | RENGRM5RORCBMP1 | |
| SCHEMBL3272138 | 0.94 | REN (0.35) | RENGRM5BMP1MKNK2HRH2 | |
| SCHEMBL4582802 | 0.94 | REN (0.35) | RENGRM5BMP1MKNK2HRH2 | |
| SCHEMBL3902921 | 0.94 | REN (0.37) | RENCYSLTR2CYSLTR1GRM5ITGB3 | |
| SCHEMBL2340320 | 0.94 | REN (0.35) | RENGRM5KDM4EALDH1A1MKNK2 | |
| SCHEMBL4592680 | 0.94 | REN (0.35) | RENGRM5KDM4EALDH1A1MKNK2 | |
| SCHEMBL2344002 | 0.94 | REN (0.34) | RENCYSLTR2CYSLTR1GRM5ITGB3 | |
| SCHEMBL1037107 | 0.93 | REN (0.36) | RENGRM5RORCBMP1 | |
| SCHEMBL2334830 | 0.93 | REN (0.34) | RENMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | REN 29/4885CYSLTR2 2774/4885CYSLTR1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.